Company intelligence / Profile preview

Equiceutica

United States

Ownership: Private
Development stage: Other

Overview

Equiceutica is a veterinary pharmaceutical company dedicated to developing and commercializing innovative therapeutic solutions for equine health. The company's primary focus is on managing pain and inflammation associated with osteoarthritis and lameness in horses, which are leading causes of performance loss and retirement in the equine industry. Their lead product, Equioxx (firocoxib), is a non-steroidal anti-inflammatory drug (NSAID) specifically formulated for horses to provide long-lasting relief from joint pain. Equiceutica aims to improve the quality of life and athletic longevity of horses through evidence-based medicine and targeted pharmacological interventions.

Therapeutic areas: Rheumatology
Modalities: Small molecule
Industry: Veterinary

Beyond the preview

Go deeper on Equiceutica.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Equiceutica.

Explore the full profile